Table 1 Summary of cancer drugs in this review
From: Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
| Rapamycin analogues | Known target | Disease |
|---|---|---|
| Temsirolimus | mTOR | Renal cell carcinoma |
| Ridaforolimus (formerly known as Deforolimus) | mTOR | Breast cancer |
| Soft tissue sarcoma | ||
| Head and neck cancer | ||
| Non-small cell lung cancer | ||
| Colorectal cancer | ||
| Everolimus | mTOR | Hormone receptor positive, HER2 negative breast cancer |
| Inhibitors/Antibodies | ||
| Letrozole | Competitive inhibitor of aromatase | Breast cancer |
| Tamoxifen | Antagonist of estrogen receptor | Breast cancer |
| Trastuzumab | HER2 receptor | Breast cancer |
| Aromasin | Aromatase inhibitor | Hormone receptor positive, HER2 negative breast cancer |
| Lapatinib | EGFR | HER2 positive breast cancer |